Earnings call transcripts

Earnings call transcripts with speakers and Q&A, usually within hours. Each one comes with a summary, the guidance management gave, and what analysts pressed on, free to read.

3,431 transcripts · 1,630 companiesHow to read a callBy API: the earnings call transcripts API.

Older calls

Page 49 of 286 · 3,431 calls

  • Veritone (VERI) Q2 2026 earnings call

    Management framed the quarter as execution through restructuring, while acknowledging delayed VDR and government deals forced a more cautious 2026 outlook.

    Aug 13, 2026Mildly positive0.10
  • XBP Global Holdings (XBP) Q2 2026 earnings call

    Management framed Q2 as a profitability and commercial-momentum inflection despite expected revenue declines from legacy exits and restructuring.

    Aug 13, 2026Positive0.65
  • York Space Systems (YSS) Q2 2026 earnings call

    Management framed the quarter around strong execution and expanding defense demand, while attributing a sharp 2026 outlook reduction to delayed awards and supply-chain slippage.

    Aug 13, 2026Cautious-0.35
  • XBP Global Holdings (XBP) Q1 2026 earnings call

    Management framed the quarter as a transition from legacy volume processing toward higher-margin AI workflows, with pipeline momentum preceding revenue conversion.

    Aug 13, 2026Mildly positive0.35
  • CXApp (CXAI) Q2 2026 earnings call

    Management framed the quarter as a strategic reset: Engine Room adds mid-market distribution, Sky 2.0 is entering production, and scale must now translate into leverage.

    Aug 13, 2026Positive0.68
  • Cineverse (CNVS) Q1 2027 earnings call

    Management framed the quarter as a post-acquisition integration inflection, with execution shifting from combining operations to capturing savings and scaling technology revenue.

    Aug 13, 2026Confident0.78
  • Applied Materials (AMAT) Q3 2026 earnings call

    Management framed the cycle as an AI-led, capacity-constrained multi-year upturn, with customers accelerating deliveries and Applied expanding readiness while avoiding precise out-year forecasts.

    Aug 13, 2026Confident0.83
  • Belite Bio (BLTE) Q2 2026 earnings call

    Management framed the call around regulatory execution, with FDA review prioritized over Europe and near-term geographic atrophy updates. Dragon 2 is not expected to contribute to the U.S.

    Aug 13, 2026Confident0.78
  • CapsoVision (CV) Q2 2026 earnings call

    Management framed the quarter as steady execution, with AI commercialization and pipeline milestones supporting stronger second-half momentum despite pricing and tariff pressure.

    Aug 13, 2026Positive0.55
  • Dare Bioscience (DARE) Q2 2026 earnings call

    Management framed the quarter as Dare’s transition from development-stage biotech to disciplined, multi-channel commercial execution.

    Aug 13, 2026Confident0.82
  • Eton Pharmaceuticals (ETON) Q2 2026 earnings call

    Management framed the quarter as proof that rapid specialty expansion can drive operating leverage while building pediatric dermatology into a major franchise.

    Aug 13, 2026Confident0.90
  • Heartflow (HTFL) Q2 2026 earnings call

    Management framed Q2 as accelerating adoption across plaque and FFRCT, with stronger confidence supporting a higher outlook and longer-term asymptomatic expansion plans.

    Aug 13, 2026Confident0.82

Companies covered

1,630 companies

154 more under A